[go: up one dir, main page]

ES2177246T3 - Formulacion farmaceutica que comprende un 2-((2-piridinil)metil)sulfinil)benzimidazol dotado de actividad antiulcerosa y procedimiento de preparacion de dicha formulacion. - Google Patents

Formulacion farmaceutica que comprende un 2-((2-piridinil)metil)sulfinil)benzimidazol dotado de actividad antiulcerosa y procedimiento de preparacion de dicha formulacion.

Info

Publication number
ES2177246T3
ES2177246T3 ES99907346T ES99907346T ES2177246T3 ES 2177246 T3 ES2177246 T3 ES 2177246T3 ES 99907346 T ES99907346 T ES 99907346T ES 99907346 T ES99907346 T ES 99907346T ES 2177246 T3 ES2177246 T3 ES 2177246T3
Authority
ES
Spain
Prior art keywords
formulation
methyl
coating
coating layer
benzimidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99907346T
Other languages
English (en)
Inventor
Kristian Lund Henriksen
Helle Kann
Karen Eichstedt Soerensen
Soeren Bols Pedersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AS
Original Assignee
GEA Farmaceutisk Fabrik AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8093069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2177246(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GEA Farmaceutisk Fabrik AS filed Critical GEA Farmaceutisk Fabrik AS
Application granted granted Critical
Publication of ES2177246T3 publication Critical patent/ES2177246T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulación farmacéutica oral que comprende 2-[[(2- piridinil)metil]sulfinil] benzimidazol como principio activo, que posee actividad antiulcerosa, comprendiendo dicha formulación gránulos que tienen una parte central sustancialmente inerte recubierta con: I) una capa interna de recubrimiento que comprende el benzimidazol, un disgregador y un tensioactivo en una matriz de una sustancia de recubrimiento fundida consistente esencialmente en uno o más ésteres de glicerol y ácidos grasos, II) una capa externa de recubrimiento que es un recubrimiento entérico, y III) una capa intermedia de recubrimiento que separa la capa de recubrimiento entérico de la capa interna de recubrimiento para la protección del benzimidazol contra la degradación por los ingredientes del recubrimiento entérico.
ES99907346T 1998-03-20 1999-03-17 Formulacion farmaceutica que comprende un 2-((2-piridinil)metil)sulfinil)benzimidazol dotado de actividad antiulcerosa y procedimiento de preparacion de dicha formulacion. Expired - Lifetime ES2177246T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK199800397A DK173431B1 (da) 1998-03-20 1998-03-20 Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs

Publications (1)

Publication Number Publication Date
ES2177246T3 true ES2177246T3 (es) 2002-12-01

Family

ID=8093069

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99907346T Expired - Lifetime ES2177246T3 (es) 1998-03-20 1999-03-17 Formulacion farmaceutica que comprende un 2-((2-piridinil)metil)sulfinil)benzimidazol dotado de actividad antiulcerosa y procedimiento de preparacion de dicha formulacion.

Country Status (20)

Country Link
US (1) US6391342B1 (es)
EP (1) EP1061920B1 (es)
AR (1) AR014753A1 (es)
AT (1) ATE218863T1 (es)
AU (1) AU744596B2 (es)
CA (1) CA2323536C (es)
CZ (1) CZ291943B6 (es)
DE (1) DE69901804T2 (es)
DK (2) DK173431B1 (es)
EA (1) EA002502B1 (es)
ES (1) ES2177246T3 (es)
HU (1) HU226580B1 (es)
IS (1) IS2265B (es)
NO (1) NO20004667L (es)
NZ (1) NZ507115A (es)
PL (1) PL192437B1 (es)
TR (1) TR200002696T2 (es)
TW (1) TW529951B (es)
WO (1) WO1999048498A1 (es)
ZA (1) ZA200004757B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020039597A1 (en) 1998-04-20 2002-04-04 Koji Ukai Stabilized compositions containing benzimidazole-type compounds
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
HRP20020006A2 (en) 1999-06-07 2003-04-30 Altana Pharma Ag Novel preparation and administration form comprising an acid-labile active compound
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
AR021347A1 (es) 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
WO2001032185A1 (en) * 1999-11-02 2001-05-10 Cipla Ltd. A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereof and a process of preparing thereof
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19959419A1 (de) * 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
ES2191521B1 (es) * 2000-11-22 2005-02-16 Laboratorios Belmac, S.A. Nueva formulacion galenica del omeprazol en forma de comprimidos, procedimiento para su preparacion y aplicaciones en medicina humana y en veterinaria.
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
WO2004089333A2 (en) * 2003-02-28 2004-10-21 Cadila Healthcare Limited A stable benzimidazole formulation
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005034923A1 (en) * 2003-10-10 2005-04-21 Ethypharm Sustained-release microgranules containing gingko biloba extract and the process for manufacturing these
US20070141150A1 (en) * 2003-12-30 2007-06-21 Raghupathi Kandarapu Pharmaceutical composition
US20050181052A1 (en) * 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
CA2558535A1 (en) * 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical composition comprising an acid labile drug
HRP20120049T1 (hr) * 2004-05-07 2012-02-29 Nycomed Gmbh Farmaceutski dozirni oblik koji obuhvaća pilule kao i postupak njegove proizvodnje
CA2570916C (en) * 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Pulsed release dosage form of a ppi
CN101426371A (zh) * 2005-12-16 2009-05-06 塔克达北美医药品公司 艾普拉唑的药物组合物
WO2007100984A2 (en) * 2006-02-24 2007-09-07 Allergan, Inc. Beads containing pyridin-sulfinyl benzoimidazole sulfonyl phenoxy acetate derivatives
EP2026768B1 (en) * 2006-06-01 2018-02-28 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20100239681A1 (en) * 2009-03-20 2010-09-23 Biokey, Inc. Controlled Release Particulates Containing Water-Insoluble Drug
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
EP2319504A1 (en) * 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CN103202820B (zh) * 2012-01-11 2016-03-30 浙江亚太药业股份有限公司 一种稳定的兰索拉唑肠溶胶囊及其制备方法
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP2020503269A (ja) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド 経口ウンデカン酸テストステロン療法
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
CA3107214A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
MA55593A (fr) 2019-04-11 2022-02-16 Janssen Pharmaceutica Nv Cycles pyridine contenant des dérivés servant d'inhibiteurs de malt1

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
ES2024993A6 (es) 1990-12-31 1992-03-01 Genesis Para La Investigacion Procedimiento de obtencion de un preparado farmaceutico oral conteniendo omeprazol.
TW209174B (es) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
EP0519144B1 (en) * 1991-06-21 1997-08-13 Ilsan Ilac Ve Hammaddeleri Sanayi A.S. New galenic process for omeprazole containing pellets
SE9200858L (sv) 1992-03-20 1993-09-21 Kabi Pharmacia Ab Metod för framställning av pellets med fördröjd frisättning
FR2692146B1 (fr) 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
WO1994002140A1 (en) 1992-07-17 1994-02-03 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
ES2087823B1 (es) 1994-07-13 1997-02-16 Estudes Et Richerches Pharma E Formulacion de microgranulos gastroresistentes de omeprazol y su procedimiento de fabricacion.
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
CH687810A5 (de) 1995-05-24 1997-02-28 Mepha Ag Pelletformulierung mit Omeprazol.
JP3463266B2 (ja) * 1995-09-21 2003-11-05 ファーマ パス エルエルシー 酸不安定性オメパラゾールを含有する新規組成物及びその製造方法
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
PT101826A (pt) 1996-02-06 1997-09-30 Medinfar Produtos Farmaceutico Processo para a preparacao de microgranulos contendo omeprazole
AU5982198A (en) 1997-03-07 1998-09-29 A/S Gea Farmaceutisk Fabrik Process for the preparation of 2-{{(2-pyridinyl)me thyl}sulfinyl}-1h-benzimidazoles and novel compounds of use for such purpos

Also Published As

Publication number Publication date
TR200002696T2 (tr) 2000-12-21
EA002502B1 (ru) 2002-06-27
PL192437B1 (pl) 2006-10-31
DK1061920T3 (da) 2002-07-15
HU226580B1 (en) 2009-04-28
DE69901804D1 (de) 2002-07-18
NZ507115A (en) 2002-09-27
CZ20003458A3 (cs) 2001-03-14
WO1999048498A1 (en) 1999-09-30
DK39798A (da) 1999-09-21
EP1061920A1 (en) 2000-12-27
CA2323536C (en) 2009-05-19
US6391342B1 (en) 2002-05-21
NO20004667L (no) 2000-11-09
ZA200004757B (en) 2001-05-30
IS5628A (is) 2000-09-13
AU744596B2 (en) 2002-02-28
EP1061920B1 (en) 2002-06-12
PL342840A1 (en) 2001-07-16
IS2265B (is) 2007-07-15
AR014753A1 (es) 2001-03-28
TW529951B (en) 2003-05-01
EA200000970A1 (ru) 2001-02-26
DK173431B1 (da) 2000-10-23
ATE218863T1 (de) 2002-06-15
AU2714899A (en) 1999-10-18
DE69901804T2 (de) 2002-12-12
CZ291943B6 (cs) 2003-06-18
CA2323536A1 (en) 1999-09-30
NO20004667D0 (no) 2000-09-19
HUP0101178A2 (hu) 2001-08-28

Similar Documents

Publication Publication Date Title
ES2177246T3 (es) Formulacion farmaceutica que comprende un 2-((2-piridinil)metil)sulfinil)benzimidazol dotado de actividad antiulcerosa y procedimiento de preparacion de dicha formulacion.
EP1051174B1 (fr) Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
CL2007002000A1 (es) Preparacion farmaceutica para la administracion oral con liberacion controlada de ingrediente activo en el intestino delgado que comprende portadores inertes, ingredientes activo, una capa interna compuesta de 2 capas de difusion para controlar la liberacion y una capa gastrorresistente; metodo de preparacion.
AR030920A1 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
ES2194732T3 (es) Composiciones farmaceuticas orales de liberacion controlada de mesalazina.
EA201892836A1 (ru) Составы 2-[3-[4-амино-3-(2-фтор-4-феноксифенил)пиразол[3,4-d]пиримидин-1-ил]пиперидин-1-карбонил]-4-метил-4-[4-(оксетан-3-ил)пиперазин-1-ил]пент-2-еннитрила с модифицированным высвобождением
ES2167891T3 (es) Estabilizacion de bencimidazoles sensibles a los acidos con combinaciones amino/ciclodextrina.
WO2005092297A3 (en) A stable pharmaceutical composition comprising an acid labile drug
DK1086694T3 (da) Oral farmaceutisk formulering i fast form med modificeret frigivelse, der indeholder en syrelabil benzimidazolforbindelse
AR100473A2 (es) Un método para la manufactura de una preparación para administración oral
AR053731A1 (es) Aromatizacion de gomas de mascar que contienen farmacos
ECSP077243A (es) Formulación de pelet de liberación extendida que contiene pramipexol o una de sus sales farmacéuticamente aceptable, un método para su fabricación y su uso
SE8004938L (sv) Farmaceutisk kompositon av fast lekemedel med fordrojd frigoring
BRPI0614417A2 (pt) composições farmacêuticas compreendendo bloqueadores de canais de cálcio de dihidropiridina e ácidos graxos de Èmega-3 e métodos de tratamento utilizando as mesmas
WO2001022791A8 (en) Controlled release compositions comprising nimesulide
KR20090086078A (ko) 항부정맥제 및 오메가-3 지방산 및 이들의 조합 생성물로의 치료
PL205865B1 (pl) Plaster zawierający warstwę przeznaczoną do pozostawania w bezpośrednim kontakcie z paznokciem i ewentualnie z otaczającą skórą oraz zastosowanie wymienionej warstwy do wytwarzania plastra
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
AR015120A1 (es) Composicion farmaceutica que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino) etoxi]bencil]-tiazolidin-2,4-diona, un procedimiento para su preparacion, y unacomposicion para la pre-administracion farmaceutica
AR024036A1 (es) Microgranulos gastroprotegidos proceso de obtencion y preparaciones farmaceuticas
CN1291077A (zh) 抗人体寄生虫和螨虫的含水制剂
EP2364145A1 (en) Dosage forms for the rapid and sustained elevation of gastric ph
EE200200368A (et) Tramadoolvesinikkloriidi sisaldav toimeainet reguleeritult vabastav ravimkoostis ja meetod selle valmistamiseks
TR200200683T2 (tr) Oral kontrollü salıverme formülasyonları.
AR038417A1 (es) Forma de dosificacion oral, procedimiento para prepararla y uso de una base debil farmaceuticamente aceptable o una sal o solvato farmaceuticamente aceptable de la misma para preparar dicha forma de dosificacion oral